Company / Cost of Revenue
Bioventus Inc. Cost of Revenue History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$179.9M
FY2025
5-year range
$90.9M / $185.1M
FY2021-FY2025
Trend
-2.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has fluctuated over the past 5 years, ranging from $91M in FY2021 to $185M in FY2024.
Based on SEC 10-K filings.
$180M in FY2025 with a 3-year CAGR of -0.2%.
Increased from $128M to $180M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -0.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -0.2%, indicating a declining trend.
- In FY2025, cost of revenue decreased 2.8% year-over-year.
- Peak cost of revenue was recorded in FY2024.
- Lowest cost of revenue in the period was in FY2021.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $179.9M | -2.8% |
| FY2024 | $185.1M | +44.4% |
| FY2023 | $128.2M | -29.2% |
| FY2022 | $181.0M | +99.1% |
| FY2021 | $90.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026